Pieris Pharmaceuticals Completes Merger With Palvella Therapeutics

Pieris Pharmaceuticals, Inc. and Palvella Therapeutics, Inc. finalized a corporate merger that resulted in the delisting of Pieris as a public company. The transaction created a combined entity operating under the Palvella Therapeutics name.

The two companies reached a definitive merger agreement on July 23, 2024. Under the terms of this agreement, Palvella Therapeutics would become a wholly owned subsidiary of Pieris, and the merged company would be known as Palvella Therapeutics, Inc.

The merger process required approval from stockholders, the effectiveness of a registration statement, and other customary closing conditions. The agreement anticipated that the transaction would be completed in the fourth quarter of 2024, pending these requirements.

On December 13, 2024, Palvella Therapeutics, Inc. completed the acquisition of Pieris Pharmaceuticals, Inc. through a reverse merger transaction. This completion marked the official combination of the two companies.

What the numbers show

• Merger agreement was signed on July 23, 2024
• The closing date of the acquisition was December 13, 2024
• The merger was subject to stockholder approval and regulatory filings

Following the completion of the merger, Pieris Pharmaceuticals ceased to exist as a separate public company. Its name no longer appears as a standalone listing on the Nasdaq exchange.

The merged company now operates solely under the Palvella Therapeutics, Inc. name. This change reflects the finalization of the reverse merger process and the integration of both organizations.

The transaction was structured so that Palvella became a wholly owned subsidiary before the combined entity adopted the Palvella Therapeutics name. The process followed the anticipated timeline set out in the original merger agreement.

According to S&P Capital IQ, the merger was completed as planned and resulted in the removal of Pieris Pharmaceuticals from public trading platforms. The new company structure is now in effect as of December 2024.

* This article is based on publicly available information at the time of writing.